|
Apr 17
|
Celldex Announces Completion of Enrollment in Phase 2 Study of Barzolvolimab in Patients with Chronic Inducible Urticaria
|
|
Apr 9
|
Down -14.61% in 4 Weeks, Here's Why You Should You Buy the Dip in Celldex (CLDX)
|
|
Apr 8
|
All You Need to Know About Celldex (CLDX) Rating Upgrade to Buy
|
|
Apr 8
|
Down -17.39% in 4 Weeks, Here's Why You Should You Buy the Dip in Celldex (CLDX)
|
|
Mar 20
|
Does Celldex (CLDX) Have the Potential to Rally 71.82% as Wall Street Analysts Expect?
|
|
Mar 8
|
Celldex Therapeutics to Participate in the Leerink Partners Global Biopharma Conference
|
|
Mar 5
|
Celldex Therapeutics to Present at TD Cowen’s 44th Annual Health Care Conference
|
|
Mar 5
|
Celldex Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares
|
|
Feb 20
|
TipRanks’‘Perfect 10’ List: These 2 Biotech Stocks Look Compelling at Current Levels
|
|
Dec 6
|
Mirati (MRTX) Up 1.1% Since Last Earnings Report: Can It Continue?
|
|
Nov 27
|
Celldex Therapeutics to Present at 6th Annual Evercore ISI HealthCONx Conference
|
|
Nov 8
|
Celldex Therapeutics Announces Pricing of Public Offering of Common Stock
|
|
Nov 7
|
Celldex Therapeutics Announces Proposed Public Offering of Common Stock
|
|
Nov 6
|
Why Celldex Therapeutics Blasted 13% Higher on Monday
|
|
Nov 6
|
Celldex Makes A Bullish Move As It Looks To Take On Regeneron, Sanofi
|
|
Nov 6
|
Celldex’s reinvention advances with inflammatory disease drug data
|
|
Nov 6
|
Celldex Therapeutics Announces Positive Topline Results from Barzolvolimab Phase 2 Study in Chronic Spontaneous Urticaria
|
|
Nov 5
|
Celldex Therapeutics Presents Positive Data from Prurigo Nodularis Phase 1b Study Demonstrating Meaningful Reduction in Itch and Skin Clearing with Single Dose 3.0 mg/kg Barzolvolimab
|
|
Nov 4
|
Celldex Therapeutics Inc (CLDX) Q3 2023 Earnings: R&D Expenses Rise Amid Progress in ...
|
|
Nov 2
|
Celldex Reports Third Quarter 2023 Financial Results and Provides Corporate Update
|